Israël - anglais - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - metformin hydrochloride; sitagliptin as phosphate salt - tablets extended release - sitagliptin as phosphate salt 50 mg; metformin hydrochloride 1000 mg - metformin - januet xr is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin extended-release is appropriate

Israël - anglais - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - metformin hydrochloride; sitagliptin as phosphate salt - tablets extended release - sitagliptin as phosphate salt 50 mg; metformin hydrochloride 500 mg - metformin - januet xr is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin extended-release is appropriate

Israël - anglais - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - elbasvir; grazoprevir - tablets - elbasvir 50 mg; grazoprevir 100 mg - elbasvir and grazoprevir - zepatier is indicated for the treatment of chronic hepatitis c (chc) genotypes 1 or 4 infection in adults

Israël - anglais - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - ertugliflozin (l-pga); metformin hydrochloride - film coated tablets - metformin hydrochloride 1000 mg; ertugliflozin (l-pga) 2.5 mg - metformin and ertugliflozin - segluromet is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:• in patients not adequately controlled on their maximally tolerated dose of metformin alone• in patients on their maximally tolerated doses of metformin in addition to other medicinal products for the treatment of diabetes • in patients already being treated with the combination of ertugliflozin and metformin as separate tablets.

Israël - anglais - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - ertugliflozin (l-pga); metformin - film coated tablets - metformin 1000 mg; ertugliflozin (l-pga) 7.5 mg - metformin and ertugliflozin - segluromet is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:• in patients not adequately controlled on their maximally tolerated dose of metformin alone• in patients on their maximally tolerated doses of metformin in addition to other medicinal products for the treatment of diabetes • in patients already being treated with the combination of ertugliflozin and metformin as separate tablets.

Israël - anglais - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - ertugliflozin (l-pga) - film coated tablets - ertugliflozin (l-pga) 15 mg - ertugliflozin - steglatro is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:• as monotherapy in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications.• in addition to other medicinal products for the treatment of diabetes.

Israël - anglais - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - ertugliflozin (l-pga) - film coated tablets - ertugliflozin (l-pga) 5 mg - ertugliflozin - steglatro is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:• as monotherapy in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications.• in addition to other medicinal products for the treatment of diabetes.

Israël - anglais - Ministry of Health

merck sharp & dohme israel ltd - alendronate as sodium - tablets - alendronate as sodium 70 mg - alendronic acid - fosalan is indicated for the treatment of osteoporosis in postmenopausal women to prevent fractures, including those of the hip and spine (vertebral compression fractures). treatment to increase bone mass in men with osteoporosis.

Israël - anglais - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - daptomycin - lyophilized powder for solution for injection - daptomycin 500 mg/vial - daptomycin - cubicin is indicated for the treatment of the infections listed below. * complicated skin and skin structure infectionscomplicated skin and skin structure infections (csssi) caused by susceptible isolates of the following gram-positive bacteria: staphylococcus aureus (including methicillin-resistant isolates), streptococcus pyogenes, streptococcus agalactiae, streptococcus dysgalactiae subsp. equisimilis, and enterococcus faecalis (vancomycin-susceptible isolates only).* staphylococcus aureus bloodstream infections (bacteremia), including those with right-sided infective endocarditis, caused by methicillin-susceptible and methicillin-resistant isolatesstaphylococcus aureus bloodstream infections (bacteremia), including those with right-sided infective endocarditis, caused by methicillin-susceptible and methicillin-resistant isolates.* combination therapy may be clinically indicated if the documented or presumed pathogens include gram negative or anaerobic organisms

Israël - anglais - Ministry of Health

merck sharp & dohme israel ltd - pembrolizumab - powder for solution for infusion - pembrolizumab 50 mg/vial - pembrolizumab - - melanoma:keytruda (pembrolizumab) is indicated for the treatment of patients with unresectable or metastatic melanoma.- non-small cell lung cancer:• keytruda, in combination with pemetrexed and carboplatin, is indicated for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (nsclc) negative for egfr or alk genomic tumor aberrations.• keytruda, in combination with carboplatin and either paclitaxel or nab-paclitaxel, is indicated for the first-line treatment of patients with metastatic squamous nsclc. • keytruda, as a single agent, is indicated for the treatment of patients with metastatic non-small cell lung cancer (nsclc) whose tumors express pd-l1 [tumor proportion score (tps) ≥50%)] as determined by a validated test. patients with egfr or alk genomic tumor aberrations should have disease progression on or after platinum-containing chemotherapy and an approved therapy for these aberrations prior to receiving keytruda.• keytruda, as a single agent, is indic